(0.17%) 5 189.41 points
(0.10%) 38 891 points
(-0.07%) 16 338 points
(0.01%) $78.49
(0.82%) $2.21
(-0.41%) $2 321.60
(-0.35%) $27.52
(2.52%) $989.25
(0.15%) $0.930
(0.73%) $10.90
(0.43%) $0.799
(-0.08%) $91.27
Quarter results tomorrow
(bmo 2024-05-08)
Expected move: +/- 11.65%
-1.01% $ 22.55
@ $35.38
Wydano: 21 kov. 2024 @ 20:07
Zwrot: -36.26%
Poprzedni sygnał: kov. 20 - 17:15
Poprzedni sygnał:
Zwrot: 1.94 %
Live Chart Being Loaded With Signals
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 792 032 |
Średni wolumen | 1.53M |
Kapitalizacja rynkowa | 1.86B |
EPS | $0 ( 2024-02-27 ) |
Następna data zysków | ( $-1.450 ) 2024-05-08 |
Last Dividend | $0.225 ( 2014-02-04 ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.11 |
ATR14 | $0.0280 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-26 | Burrell Terry-ann | Buy | 12 500 | Common Stock |
2024-04-26 | Burrell Terry-ann | Buy | 25 000 | Stock Option (Right to Buy) |
2024-04-01 | Simon Amy | Sell | 7 157 | Common Stock |
2024-04-02 | Simon Amy | Sell | 16 530 | Common Stock |
2024-04-01 | Bellon Christine | Sell | 3 401 | Common Stock |
INSIDER POWER |
---|
-11.09 |
Last 98 transactions |
Buy: 1 537 714 | Sell: 1 873 404 |
Wolumen Korelacja
Beam Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
TUEM | 0.951 |
TWST | 0.942 |
CSSE | 0.929 |
ROST | 0.927 |
MDRX | 0.926 |
RKDA | 0.924 |
AFIB | 0.923 |
HMST | 0.923 |
AGIO | 0.922 |
ATSG | 0.922 |
10 Najbardziej negatywne korelacje | |
---|---|
WIRE | -0.933 |
CPTA | -0.928 |
TYHT | -0.928 |
ZGNX | -0.926 |
HTBI | -0.92 |
VC | -0.92 |
PAE | -0.919 |
SGEN | -0.919 |
RAM | -0.916 |
EBSB | -0.91 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Beam Therapeutics Inc Korelacja - Waluta/Towar
Beam Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $377.71M |
Zysk brutto: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2023 |
Przychody: | $377.71M |
Zysk brutto: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2022 |
Przychody: | $60.92M |
Zysk brutto: | $38.34M (62.94 %) |
EPS: | $-3.76 |
FY | 2021 |
Przychody: | $51.84M |
Zysk brutto: | $51.84M (100.00 %) |
EPS: | $-5.77 |
Financial Reports:
No articles found.
Beam Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.190 | 2011-11-07 |
Last Dividend | $0.225 | 2014-02-04 |
Next Dividend | $0 | N/A |
Payout Date | 2014-03-03 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.16 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.6 | -- |
Div. Sustainability Score | 1.443 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.318 | 1.500 | -6.36 | -9.54 | [0 - 0.5] |
returnOnAssetsTTM | -0.0823 | 1.200 | -2.74 | -3.29 | [0 - 0.3] |
returnOnEquityTTM | -0.144 | 1.500 | -2.71 | -4.07 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.79 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.12 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.119 | -1.500 | 8.02 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -5.10 | 1.000 | -3.00 | -3.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -1.131 | -2.26 | [0 - 20] |
debtEquityRatioTTM | 0.176 | -1.500 | 9.29 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.928 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.467 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.862 | 1.000 | -5.90 | -5.90 | [0.2 - 2] |
assetTurnoverTTM | 0.259 | 0.800 | -1.608 | -1.287 | [0.5 - 2] |
Total Score | 1.443 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -15.34 | 1.000 | -1.650 | 0 | [1 - 100] |
returnOnEquityTTM | -0.144 | 2.50 | -1.744 | -4.07 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -0.754 | -2.26 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.287 | 1.500 | -5.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.395 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.66 |
Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej